Given the prior Waylivra Complete Response Letter issued by the FDA, the positive Committee for Medicinal Products for Human Use opinion announced this morning was a surprise to many, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst anticipates a European Medicines Agency approval in the coming months and models $150M in European Waylivra sales by the late 2020s "with minimal increase in long-term operating spending." As a result, the analyst boosted his price target for Ionis Pharmaceuticals to $63 from $60 while keeping a Neutral rating on the shares.